Importance The introduction of immune checkpoint inhibitors (ICIs) has transformed the care
of advanced non–small cell lung cancer (NSCLC). Although clinical trials suggest …

Importance Immunotherapy is now a cornerstone of treatment for advanced non–small cell
lung cancer (NSCLC), but its uptake and effectiveness among older patients outside clinical …

Background Limited data exist regarding the characteristics and survival outcomes of older
adults with non–small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors …

Importance For patients with advanced non–small cell lung cancer (NSCLC) treated with
frontline immunotherapy-based treatment, the optimal duration of immune checkpoint …

Background Age-related immune remodelling is thought to be associated with resistance to
immune checkpoint inhibitors (ICIs) in cancer. Patients older than 70 years, representing> …

OBJECTIVE To evaluate the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in
older patients with advanced non–small cell lung cancer (NSCLC) seen in routine clinical …

Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐
small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in …

Background Adults with impaired performance status (PS) often receive immune checkpoint
inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy …

Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape
among non-small-cell lung cancer (NSCLC) patients. The efficacy of ICI therapy in older …

Background Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a
subset of patients, consistent and easily obtainable predictors of efficacy remain elusive …